Citation Impact
Citing Papers
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
2009
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers
2012
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
2015
Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
2014
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
2012
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Evolution of the Cancer Stem Cell Model
2014 Standout
Extracellular vesicles and particles impact the systemic landscape of cancer
2022
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
2018
Cancer statistics, 2023
2023 Standout
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
2013
Cancer statistics, 2024
2024 Standout
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
2017
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials
2014
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Hepatocellular carcinoma
2016 Standout
The role of porphyrin chemistry in tumor imaging and photodynamic therapy
2010 Standout
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
2011
Evaluation of Pulmonary Nodules
2016
Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action
2005
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Endocan: A novel inflammatory indicator in cardiovascular disease?
2015 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
2007
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
2021 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Complex cocktails: the evolutionary novelty of venoms
2012 Standout
From snake venom toxins to therapeutics – Cardiovascular examples
2011
Angiogenesis: an organizing principle for drug discovery?
2007 Standout
Serum endocan levels as a marker of disease activity in patients with Behçet disease
2013
Drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer
2016
Clinical Trials with Oncolytic Adenovirus in China
2007
Radiation-Induced Lung Injury (RILI)
2019
Lung cancer: current therapies and new targeted treatments
2016 Standout
Treating ALK-positive lung cancer—early successes and future challenges
2012
The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer
2012
Acute kidney injury
2019 Standout
A review of the benefit–risk profile of gefitinib in Asian patients with advanced non‐small‐cell lung cancer
2006
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
2017
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
2017 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
EMT: 2016
2016 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
2015
Recent agents targeting HIF‐1α for cancer therapy
2012
Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease
2014
EGFR tyrosine kinase inhibitorsversuschemotherapy inEGFRwild-type pre-treated advanced nonsmall cell lung cancer in daily practice
2017
Coming of age: ten years of next-generation sequencing technologies
2016 Standout
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
2016
Crizotinib in the Treatment of Non–Small-Cell Lung Cancer
2013
Endocan, a new invasion and angiogenesis marker of pituitary adenomas
2014
Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer
2012
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
2015
Neutrophils in cancer: neutral no more
2016 Standout
Implications of the tumor immune microenvironment for staging and therapeutics
2017
Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone
2006
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
2013
Glycosylation in cancer: mechanisms and clinical implications
2015 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial
2017
The first 30 years of p53: growing ever more complex
2009 Standout
The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
2016
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)
2015
Hyperprogressive disease: recognizing a novel pattern to improve patient management
2018
Spontaneous and Controllable Activation of Suicide Gene Expression Driven by the Stress-Inducible Grp78 Promoter Resulting in Eradication of Sizable Human Tumors
2004
Heterogeneity and cancer.
2014
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytesin vitro
2008
Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification
2012
Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease
2013
Regulatory T Cells and Human Disease
2020 StandoutNobel
Targeting Treg cells in cancer immunotherapy
2019 StandoutNobel
Cancer statistics in China, 2015
2016 Standout
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor
2014
Muc1 Immunotherapy
2010
Chemotherapy for advanced gastric cancer
2017 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Prevention and management of lung cancer in China
2015
Effect of CPAP on New Endothelial Dysfunction Marker, Endocan, in People With Obstructive Sleep Apnea
2015
Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer
2022
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
2013
Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?
2013
Endocan—A Novel Inflammatory Indicator in Newly Diagnosed Patients With Hypertension
2014 Standout
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine
2014
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review
2016
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
2014
Regulatory T cells expressing abundant CTLA‐4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer
2018 StandoutNobel
Works of Qing Zhou being referenced
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
2016
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
2017
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
2010
Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
2015
Lung Cancer Management in the Asia-Pacific Region: What's the Difference Compared with the United States and Europe? Results of the Second Asia Pacific Lung Cancer Conference
2007
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer
2010
Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis
2012
Expression and distribution of endocan in human tissues
2011
Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status
2012
Contortrostatin, a dimeric disintegrin from contortrix contortrix, inhibits breast cancer progression
2000
An Autologous Therapeutic Dendritic Cell Vaccine Transfected with Total Lung Carcinoma RNA Stimulates Cytotoxic T Lymphocyte Responses Against Non-Small Cell Lung Cancer
2009
Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China
2007
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer
2012
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial
2014
Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer.
2011
A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806).
2013
EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
2012
Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
2011
EGFR mutations in lung cancers and sensitivity to gefitinib in Chinese
2005
[Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer].
2003
Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients
2005
[Association of XAGE-1b gene expression with clinical characteristics of non-small cell lung cancer].
2007
Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
2020
Research and Standard Care: Lung Cancer in China
2012
Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
2010